robert fremeau | Founder and CEO
BrainStorm Therapeutics, Inc.

Dr. Fremeau is an accomplished molecular neuroscientist and biotech entrepreneur with a distinguished record of scientific innovation and leadership at the intersection of target validation, translation, and clinical development. As the Founder and CEO of BrainStorm Therapeutics, he is pioneering the development of an AI-powered human brain organoid platform to identify therapeutic candidates to halt, prevent, or reverse synaptic dysfunction and neurodegeneration. Previously, as CSO at Vyant Bio, Dr. Fremeau led the company’s transformation from a services and manufacturing organization into a fully integrated drug discovery platform. Under his leadership, Vyant Bio advanced a promising pipeline of therapies for genetic neurodevelopmental disorders, including Rett syndrome and CDKL5 deficiency disorder. Notably, his team identified novel clinical candidates for Rett syndrome through phenotypic screening of patient-derived cortical organoids, advancing these candidates into a Phase 2 clinical trial supported by a U.S. Department of Defense grant. Before transitioning to industry, Dr. Fremeau had a distinguished academic career, holding faculty positions at the University of California, San Francisco and Duke University Medical School. His pioneering work on the molecular and functional characterization of receptors and transporters for biogenic amine and amino acid neurotransmitters set a foundation for much of modern neuropharmacology. Dr. Fremeau’s research has resulted in over 65 peer-reviewed publications in leading scientific journals and multiple patents. He has served on the editorial board of Molecular Pharmacology and as a reviewer for the National Institute of Neurological Disorders and Stroke (NINDS) and the National Science Foundation (NSF). He conducted his postdoctoral research in Molecular Neurobiology at Columbia University College of Physicians and Surgeons and holds a PhD in Biochemistry from George Washington University Medical Center.